An Introduction to Stroke
Most strokes (85%) are caused by acute ischaemia due to blockage of a cerebral artery, leading to loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral or subarachnoid haemorrhage. Treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytics and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. Increasingly, oral anticoagulants are preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia (e.g. transplantation of mesenchymal stem cells) are also emerging as potentially useful.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Multidisciplinary insights on the role of GLP-1 RAs in the modern management of stroke in patients with T2D
A multidisciplinary team and a patient discuss GLP-1 RAs and their role in stroke prevention in patients with T2D.
- Describe the burden of stroke and risk factors for stroke in patients with T2D
- Evaluate the latest data for GLP-1 RAs in the context of stroke management and prevention
- Interpret current treatment guidelines for T2D in the context of stroke management and prevention and apply it to clinical practice
Computed Tomography Perfusion Deficit as an Indicator for Reperfusion in Large-vessel Occlusions with Low National Institutes of Health Stroke Scale Scores in Acute Ischaemic Stroke: A Retrospective Review
touchREVIEWS in Neurology 2022;18(2): 147-52 DOI: https://doi.org/10.17925/USN.2022.18.2.147
In clinical practice, the definition of penumbra is largely based on neuroimaging and indicates potentially salvageable tissue. Perfusion imaging has been useful in identifying this tissue when obeying ‘the mismatch concept’. The mismatch concept is a surrogate marker for salvageable brain tissue and refers to a lesion volume difference (mismatch) between the perfusion deficit (the […]
Hariklia Proios, Stroke Alliance for Europe (SAFE): Presidential Update
The Stroke Alliance for Europe (SAFE) is a non-profit-making organisation that represents a range of patient groups from across Europe. Their mutual goal is to drive stroke prevention up the European political agenda and prevent the incidence of stroke through education. touchNEUROLOGY caught up with the SAFE President, Prof. Hariklia (Harriet) Proios, to discuss the […]
Martin Bretzner, ESOC 2022: Brain-age biomarkers to predict post-stroke recovery
Brain-age biomarkers can be used to predict post-stroke recovery. Dr Martin Bretzner (Lille Neuroscience & Cognition Research Centre, Lille University Hospital, Lille, France) discusses the results of a study using radiomics, an emerging image-quantifying technology to assess ‘brain-age’ biomarkers. The study investigates how relative brain age, rather than chronological age, can enhance stroke surveillance and […]
Miquel Lledós, ESOC 2022: The influence of gut microbiome on ischaemic stroke risk and outcome
The composition of the gut microbiome is a modifiable factor associated with the risk of ischaemic stroke and post-stroke neurological outcome. Dr Miquel Lledós (Stroke Pharmacogenomics and Genetics Laboratory, Sant Pau Research Institute, Barcelona, Spain) discusses the outcome of a study using faecal samples to demonstrate the influence of the gut microbiome on ischaemic stroke […]
Highlighting SAP-E successes on European Stroke Awareness Day
On behalf of the European Stroke Organisation (ESO) and Stroke Alliance for Europe (SAFE), touchNEUROLOGY are pleased to share the progress made toward reaching the 4 overarching targets of the Stroke Action Plan for Europe (SAP-E). Led by ESO and SAFE, the SAP-E initiative aims to encourage European countries to show their commitment to improving stroke prevention, treatment, care and […]
Collavidence: Accelerating Stroke Research – an interview with Rosalie McDonough, Johanna Ospel and Arnuv Mayank
Dr Rosalie McDonough became the CEO of Collavidence Inc. through a rather unconventional pathway. During her graduate studies in molecular biology and genetics at McGill University, she experienced first-hand the struggles researchers faced trying to get their work funded. After finishing the program with a Master’s of Science she moved to Germany to attend medical […]
European Stroke Organisation Conference 2022: Looking Forward to World-class Scientific Discoveries and Live Discussion
Dr Else Charlotte Sandset, ESO Secretary General and Consultant Neurologist at the Stroke Unit, Department of Neurology, Oslo University Hospital, Norway, provides an overview of some of the high-quality research and scientific advances the stroke community can look forward to at the 8th European Stroke Organisation Conference (ESOC 2022) in Lyon, France and online from 4–6 May 2022.
A Review of Potential Mechanisms of Cryptogenic Stroke and a Recommended Approach to Diagnosis
touchREVIEWS in Neurology. 2021;17(2): 104–9 DOI: https://doi.org/10.17925/USN.2021.17.2.104
Ischaemic stroke may occur due to several potential mechanisms. Mechanisms are classically described as large artery atherosclerosis, small-vessel occlusion, cardioembolism, stroke of other determined aetiology (i.e. vasculitis, genetic disorder, etc.) and stroke of undetermined aetiology. Historically, the definition of stroke of undetermined aetiology has included strokes with multiple potential mechanisms, as well as those with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!